Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacogenomic Markers of Clopidogrel Resistance in Malaysian CAD Patients: Clinical Efficacy and Economic Evaluation of CYP2C19 Genotype-Guided Therapy

NCT06759272 is registered in ClinicalTrials.gov with Nur Hafizah Annezah binti Utuh as lead sponsor.

NCT NCT06759272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06759272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacogenomic Markers of Clopidogrel Resistance in Malaysian CAD Patients: Clinical Efficacy and Economic Evaluation of CYP2C19 Genotype-Guided Therapy
Lead sponsor
Nur Hafizah Annezah binti Utuh
Phase
Phase 4
Overall status
Not yet recruiting
Start date
February 28, 2025
Completion date
February 28, 2026
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acs (acute coronary syndrome), coronary arterial disease (cad), scad